Adell Harriman & Carpenter Inc Biogen Inc. Transaction History

Adell Harriman & Carpenter Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 07, 2019	SELL	$219.29 - $241.72 $516,427 - $569,250	-2,355 Closed	0 $0
Q1 2019 May 07, 2019	SELL	$216.71 - $338.96 $481,312 - $752,830	-2,221 Reduced 48.54%	2,355 $0
Q4 2018 Feb 08, 2019	SELL	$278.5 - $352.75 $24,786 - $31,394	-89 Reduced 1.91%	4,576 $1.38 Million
Q3 2018 Nov 14, 2018	SELL	$293.51 - $383.83 $76,606 - $100,179	-261 Reduced 5.3%	4,665 $0
Q2 2018 Aug 06, 2018	SELL	$257.52 - $306.91 $320,612 - $382,102	-1,245 Reduced 20.18%	4,926 $0
Q1 2018 May 08, 2018	SELL	$260.13 - $367.91 $66,333 - $93,817	-255 Reduced 3.97%	6,171 $0
Q4 2017 Feb 05, 2018	BUY	$307.64 - $344.58 $61,528 - $68,916	200 Added 3.21%	6,426 $0
Q3 2017 Nov 06, 2017	BUY	$281.15 - $329.69 $1.75 Million - $2.05 Million	6,226	6,226 $0

990

131M

1.12M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Adell Harriman & Carpenter Inc, based on Form 13F filings with the SEC.

Stay updated on Adell Harriman & Carpenter Inc with notifications on news.